Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy, a time to start and a time to stop

被引：17
作者：
Adrichem, Max E. [1 ]
Eftimov, Filip [1 ]
van Schaik, Ivo N. [1 ]
机构：
[1] Acad Med Ctr Amsterdam, Dept Neurol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
来源：
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM | 2016年 / 21卷 / 03期
关键词：
CIDP; IVIg; long-term treatment; RANDOMIZED CONTROLLED TRIAL; NEONATAL FC-RECEPTOR; IMMUNE GLOBULIN; IVIG RESPONSIVENESS; POLYNEUROPATHY; INFUSION; THERAPY; CIDP; IGG; METHYLPREDNISOLONE;
D O I：
10.1111/jns.12176
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Intravenous immunoglobulin (IVIg) is often used as preferred treatment in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Several studies highlighted the short-term efficacy of IVIg for CIDP yet many patients need maintenance therapy. Notwithstanding the fact IVIg has been used for over 30 years in CIDP, there is only limited evidence to guide dosage and interval during maintenance treatment. The variation in disease course, lack of biomarkers, and fear of deterioration after stopping IVIg makes long-term treatment challenging. Recent studies suggest a proportion of patients receive unnecessary IVIg maintenance treatment. This review provides an overview of the use of IVIg for CIDP treatment, focusing on evidence for long-term IVIg use.
引用
收藏
页码：121 / 127
页数：7
相关论文
共 50 条
[41]   Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in chronic inflammatory demyelinating polyradiculoneuropathy: protocol of an international, randomised, double-blind, placebo-controlled trial (OPTIC) [J].
S. R. M. Bus ;
L. Zambreanu ;
A. Abbas ;
Y. A. Rajabally ;
R. D. M. Hadden ;
R. J. de Haan ;
C. A. J. M. de Borgie ;
M. P. Lunn ;
I. N. van Schaik ;
F. Eftimov .
Trials, 22
[42]   Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy [J].
Goyal, Namita A. ;
Karam, Chafic ;
Sheikh, Kazim A. ;
Dimachkie, Mazen M. .
MUSCLE & NERVE, 2021, 64 (03) :243-254
[43]   Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Revisiting the Role of Intravenous Immmunoglobulins [J].
Chapman, Joab ;
Shoenfeld, Yehuda .
ISRAEL MEDICAL ASSOCIATION JOURNAL, 2013, 15 (06) :293-294
[44]   Autoantibodies in chronic inflammatory demyelinating polyradiculoneuropathy [J].
Pascual-Goni, Elba ;
Martin-Aguilar, Lorena ;
Querol, Luis .
CURRENT OPINION IN NEUROLOGY, 2019, 32 (05) :651-657
[45]   Immunotherapy of chronic inflammatory demyelinating polyradiculoneuropathy [J].
Eftimov, F. ;
van Schaik, I. N. .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (05) :643-655
[46]   Safety and Cost Analysis of Immunoglobulin Cessation Trials in Chronic Inflammatory Demyelinating Polyradiculoneuropathy [J].
Koay, Shiwen ;
Chen, Yi-Chun ;
Ransley, George ;
Compton, Laura ;
Lunn, Michael P. ;
Carr, Aisling S. .
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2025, 30 (01)
[47]   Clinical-neurophysiological correlations in chronic inflammatory demyelinating polyradiculoneuropathy patients treated with subcutaneous immunoglobulin [J].
Cirillo, Giovanni ;
Todisco, Vincenzo ;
Ricciardi, Dario ;
Tedeschi, Gioacchino .
MUSCLE & NERVE, 2019, 60 (06) :662-667
[48]   Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy [J].
Hughes, Richard A. C. ;
Mehndiratta, Man Mohan .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (01)
[49]   Safety and Tolerability of Immune Globulin Intravenous in Chronic S Inflammatory Demyelinating Polyradiculoneuropathy [J].
Donofrio, Peter D. ;
Bril, Vera ;
Dalakas, Marinos C. ;
Deng, Chunqin ;
Hanna, Kim ;
Hartung, Hans-Peter ;
Hughes, Richard ;
Latov, Norman ;
Merkies, Ingemar ;
van Doorn, Pieter .
ARCHIVES OF NEUROLOGY, 2010, 67 (09) :1082-1088
[50]   Chronic inflammatory demyelinating polyradiculoneuropathy in patients with diabetes mellitus-treatment with intravenous immunoglobulins: A systematic review [J].
Andrusiow, Szymon ;
Pawlak, Zuzanna ;
Stanczykiewicz, Bartlomiej ;
Bogunia-Kubik, Katarzyna ;
Koszewicz, Magdalena .
BIOMEDICINE & PHARMACOTHERAPY, 2023, 164
12345